Treos Bio Limited products
Treos - Personal Antigen Selection Calculator Technologies (PASCal)
At TREOS we use knowledgebase and algorithm embedded in PASCal (Personal Antigen Selection Calculator) tool to develop personal cancer immunotherapies. PASCal supports the development of immunotherapies for single individuals and a population of individuals with a specific genetic background, including specific peptides most effective in ethnic populations.
Treos - Predictive Diagnostic Tests Technology
At TREOS we discovered that an individual’s HLA genotype is the main determinant of immune responses. This breakthrough led to the development of the PEPI Test (CE Marked) that predicts peptide-specific T cell responses of HLA genotyped individuals. Based on the PEPI Test we have been co-developing with each PolyPEPI™ product a Companion Diagnostic to predict likely responders and improve the diagnostic repertoire of practicing clinicians.
Off-the-Shelf Personalized Peptide Cancer Immunotherapies Technology
PEPI Panel – A unique approach for personalized cancer immunotherapy generation. Our Peptide Library (PEPI Panel) currently contains 3,286 proprietary, immunogenic peptide fragments from 184 tumor antigens associated with 19 cancer indications that induce immune responses in the largest subpopulation of subjects, based on HLA genotype (both class I and II) of 16,000 subjects. PEPI Panel approach guides selection of 12 individual peptides tailored to the tumor type and HLA genotype of patients from a warehouse of off-the-shelf peptides permitting rapid, efficient manufacture of a personalized immunotherapy. Treos’ differentiated and scalable approach provides substantial competitive advantage over all other approaches in the personalized cancer immunotherapy field, and offers an exclusive opportunity to produce personalized products faster and cheaper.
Treos - SCoV-2 Covid Preventive Vaccines
Using our proprietary computational vaccine design technology, we have developed a PolyPEPI preventive peptide vaccine against COVID-19 (SARS-CoV-2). The design of PolyPEPI-SCoV-2 exploits our knowledge on genetic heterogeneity of individuals and ethnicities. PolyPEPI-SCoV-2 vaccine can elicit broad and long-lasting immune responses in vaccinated subjects and can therefore protect people against COVID-19, worldwide. PolyPEPI-SCoV-2 product contains 9 different peptide fragments from the four structural protein of the virus. Mutations of the virus will not affect the global coverage of our vaccine; the majority of subjects are expected to have a broad repertoire of virus-specific memory.
Treos - Off-the-Shelf Peptide Cancer Immunotherapies Technology
Off-the-shelf products contain 6-12 shared tumor-specific antigen derived peptides optimized for a population. They are personalized with a candidate companion diagnostic test (CDx). In silico trials predicted that these peptides induce exceptionally broad T cell responses against at least 3 tumor-specific antigens in high proportion of patients, without need of biopsy. Phase 1 clinical study is completed to confirm the predictions in patients with metastatic colorectal cancer (NCT03391232, Hubbard et al ASCO 2020).